XML 65 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1

Segments (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Segment Profit

		Year ended December 31,
		2021
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	7,809			$	4,886			$	2,032
Gross profit			4,226				2,823				1,118
R&D expenses			618				244				68
S&M expenses			988				846				417
G&A expenses			427				244				109
Other income			(31	)			(5	)			(5	)
Segment profit		$	2,224			$	1,494			$	529

		Year ended December 31,
		2020
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	8,447			$	4,757			$	2,154
Gross profit			4,489				2,666				1,096
R&D expenses			622				247				70
S&M expenses			1,013				830				427
G&A expenses			443				261				136
Other income			(10	)			(3	)			(11	)
Segment profit		$	2,421			$	1,331			$	474

		Year ended December 31,
		2019
		North America				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	8,542			$	4,795			$	2,246
Gross profit			4,350				2,704				1,167
R&D expenses			652				262				88
S&M expenses			1,021				890				481
G&A expenses			439				239				138
Other income			(14	)			(5	)			(3	)
Segment profit		$	2,252			$	1,318			$	464

Schedule Of Consolidated Income Before Income Tax

		Year ended
		December 31,
		2021				2020				2019
		(U.S. $ in millions)
North America profit		$	2,224			$	2,421			$	2,252
Europe profit			1,494				1,331				1,318
International Markets profit			529				474				464
Total reportable segments profit			4,246				4,225				4,034
Profit of other activities			154				163				108
Total segments profit			4,401				4,388				4,142
Amounts not allocated to segments:
Amortization			802				1,020				1,113
Other assets impairments, restructuring and other items			341				479				423
Goodwill impairment			—				4,628				—
Intangible asset impairments			424				1,502				1,639
Legal settlements and loss contingencies			717				60				1,178
Other unallocated amounts			402				271				232
Consolidated operating income (loss)			1,716				(3,572	)			(443	)
Financial expenses, net			1,058				834				822
Consolidated income (loss) before income taxes		$	658			$	(4,406	)		$	(1,265	)

Schedule of Net Sales by Product Line

North America segment:

		Year ended December 31,
		2021				2020				2019
		(U.S. $ in millions)
Generic products		$	3,769			$	4,010			$	3,963
AJOVY			176				134				93
AUSTEDO			802				637				412
BENDEKA/TREANDA			385				415				496
COPAXONE			577				884				1,017
ProAir*			180				241				274
Anda			1,323				1,462				1,492
Other			597				664				796
Total		$	7,809			$	8,447			$	8,542

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

Europe segment:

		Year ended December 31,
		2021				2020				2019
		(U.S. $ in millions)
Generic products		$	3,569			$	3,513			$	3,470
AJOVY			87				31				3
COPAXONE			391				400				432
Respiratory products			356				353				354
Other			483				459				536
Total		$	4,886			$	4,757			$	4,795

International Markets segment:

		Year ended December 31,
		2021				2020				2019
		(U.S. $ in millions)
Generic products		$	1,649			$	1,792			$	1,893
AJOVY			50				18				§
COPAXONE			37				53				63
Other			295				291				291
Total		$	2,032			$	2,154			$	2,246

§ Represents an amount less than $1 million.

Schedule of Sales Percentage by Therapeutic Category

The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2021, 2020 and 2019.

		Percentage of Third Party Net Sales
		2021				2020				2019
McKesson Corporation			11	%			12	%			13	%
AmerisourceBergen Corporation			11	%			12	%			12	%

Schedule of Property, Plant and Equipment by Geographic Location

		December 31,
		2021				2020
		(U.S. $ in millions)
Israel		$	1,543			$	1,611
United States			692				790
Croatia			481				539
Germany			1,045				933
Czech republic			324				330
Hungary			321				325
Ireland			269				267
Other			1,307				1,501
Total property, plant and equipment		$	5,982			$	6,296

X

- Definition

A schedule indicating where long-lived tangible assets are located.

+ References

No definition available.

+ Details

Name:	teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

A schedule of net sales by therapeutic category, stated as a percentage of total sales.

+ References

No definition available.

+ Details

Name:	teva_SalesPercentageByTherapeuticCategoryTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration